Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease

T. S. Plantinga; P. Arts; G. H. Knarren; A. H. Mulder; I. M. Wakelkamp; A. R. Hermus; L. A. Joosten; M. G. Netea; P. H. Bisschop; W. W. de Herder; H. J. Beijers; I. J. de Bruin; C. Gilissen; J. A. Veltman; A. Hoischen; J. W. Smit; R. T. Netea-Maier

doi:https://doi.org/10.1002/cpt.733

Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease

T. S. Plantinga, P. Arts, G. H. Knarren, A. H. Mulder, I. M. Wakelkamp, A. R. Hermus, L. A. Joosten, M. G. Netea, P. H. Bisschop, W. W. de Herder, H. J. Beijers, I. J. de Bruin, C. Gilissen, J. A. Veltman, A. Hoischen, J. W. Smit, R. T. Netea-Maier

Research output: Contribution to journal › Article › Academic › peer-review

10 Citations (Scopus)

Abstract

Agranulocytosis is a rare and serious adverse effect of antithyroid drugs, with unknown etiology. The present study aimed to uncover genetic susceptibility and underlying mechanisms of antithyroid drug-induced agranulocytosis (ATDAC). We studied two independent families with familial Graves' disease, of which several members developed ATDAC. In addition, six sporadic ATDAC patients with Graves' disease were investigated. Whole exome sequencing analysis of affected and unaffected family members was performed to identify genetic susceptibility variants for ATDAC, followed by functional characterization of primary granulocytes from patients and unrelated healthy controls. Whole exome sequencing, cosegregation analysis, and stringent selection criteria of candidate gene variants identified NOX3 as a genetic factor related to ATDAC. Functional studies revealed increased apoptosis of methimazole-treated granulocytes from patients carrying NOX3 variants. In conclusion, genetic variants in NOX3 may confer susceptibility to antithyroid drug-induced apoptosis of granulocytes. These findings contribute to the understanding of the mechanisms underlying ATDAC

Original language	English
Pages (from-to)	1017-1024
Journal	Clinical Pharmacology and Therapeutics
Volume	102
Issue number	6
Early online date	2017
DOIs	https://doi.org/10.1002/cpt.733
Publication status	Published - 2017

Access to Document

https://doi.org/10.1002/cpt.733

Cite this

Plantinga, T. S., Arts, P., Knarren, G. H., Mulder, A. H., Wakelkamp, I. M., Hermus, A. R., Joosten, L. A., Netea, M. G., Bisschop, P. H., de Herder, W. W., Beijers, H. J., de Bruin, I. J., Gilissen, C., Veltman, J. A., Hoischen, A., Smit, J. W., & Netea-Maier, R. T. (2017). Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease. Clinical Pharmacology and Therapeutics, 102(6), 1017-1024. https://doi.org/10.1002/cpt.733

@article{901d2e9ecb7f4403b39503e4dd9b6c1b,

title = "Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease",

abstract = "Agranulocytosis is a rare and serious adverse effect of antithyroid drugs, with unknown etiology. The present study aimed to uncover genetic susceptibility and underlying mechanisms of antithyroid drug-induced agranulocytosis (ATDAC). We studied two independent families with familial Graves' disease, of which several members developed ATDAC. In addition, six sporadic ATDAC patients with Graves' disease were investigated. Whole exome sequencing analysis of affected and unaffected family members was performed to identify genetic susceptibility variants for ATDAC, followed by functional characterization of primary granulocytes from patients and unrelated healthy controls. Whole exome sequencing, cosegregation analysis, and stringent selection criteria of candidate gene variants identified NOX3 as a genetic factor related to ATDAC. Functional studies revealed increased apoptosis of methimazole-treated granulocytes from patients carrying NOX3 variants. In conclusion, genetic variants in NOX3 may confer susceptibility to antithyroid drug-induced apoptosis of granulocytes. These findings contribute to the understanding of the mechanisms underlying ATDAC",

author = "Plantinga, {T. S.} and P. Arts and Knarren, {G. H.} and Mulder, {A. H.} and Wakelkamp, {I. M.} and Hermus, {A. R.} and Joosten, {L. A.} and Netea, {M. G.} and Bisschop, {P. H.} and {de Herder}, {W. W.} and Beijers, {H. J.} and {de Bruin}, {I. J.} and C. Gilissen and Veltman, {J. A.} and A. Hoischen and Smit, {J. W.} and Netea-Maier, {R. T.}",

year = "2017",

doi = "https://doi.org/10.1002/cpt.733",

language = "English",

volume = "102",

pages = "1017--1024",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "6",

}

Plantinga, TS, Arts, P, Knarren, GH, Mulder, AH, Wakelkamp, IM, Hermus, AR, Joosten, LA, Netea, MG, Bisschop, PH, de Herder, WW, Beijers, HJ, de Bruin, IJ, Gilissen, C, Veltman, JA, Hoischen, A, Smit, JW & Netea-Maier, RT 2017, 'Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease', Clinical Pharmacology and Therapeutics, vol. 102, no. 6, pp. 1017-1024. https://doi.org/10.1002/cpt.733

TY - JOUR

T1 - Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease

AU - Plantinga, T. S.

AU - Arts, P.

AU - Knarren, G. H.

AU - Mulder, A. H.

AU - Wakelkamp, I. M.

AU - Hermus, A. R.

AU - Joosten, L. A.

AU - Netea, M. G.

AU - Bisschop, P. H.

AU - de Herder, W. W.

AU - Beijers, H. J.

AU - de Bruin, I. J.

AU - Gilissen, C.

AU - Veltman, J. A.

AU - Hoischen, A.

AU - Smit, J. W.

AU - Netea-Maier, R. T.

PY - 2017

Y1 - 2017

N2 - Agranulocytosis is a rare and serious adverse effect of antithyroid drugs, with unknown etiology. The present study aimed to uncover genetic susceptibility and underlying mechanisms of antithyroid drug-induced agranulocytosis (ATDAC). We studied two independent families with familial Graves' disease, of which several members developed ATDAC. In addition, six sporadic ATDAC patients with Graves' disease were investigated. Whole exome sequencing analysis of affected and unaffected family members was performed to identify genetic susceptibility variants for ATDAC, followed by functional characterization of primary granulocytes from patients and unrelated healthy controls. Whole exome sequencing, cosegregation analysis, and stringent selection criteria of candidate gene variants identified NOX3 as a genetic factor related to ATDAC. Functional studies revealed increased apoptosis of methimazole-treated granulocytes from patients carrying NOX3 variants. In conclusion, genetic variants in NOX3 may confer susceptibility to antithyroid drug-induced apoptosis of granulocytes. These findings contribute to the understanding of the mechanisms underlying ATDAC

AB - Agranulocytosis is a rare and serious adverse effect of antithyroid drugs, with unknown etiology. The present study aimed to uncover genetic susceptibility and underlying mechanisms of antithyroid drug-induced agranulocytosis (ATDAC). We studied two independent families with familial Graves' disease, of which several members developed ATDAC. In addition, six sporadic ATDAC patients with Graves' disease were investigated. Whole exome sequencing analysis of affected and unaffected family members was performed to identify genetic susceptibility variants for ATDAC, followed by functional characterization of primary granulocytes from patients and unrelated healthy controls. Whole exome sequencing, cosegregation analysis, and stringent selection criteria of candidate gene variants identified NOX3 as a genetic factor related to ATDAC. Functional studies revealed increased apoptosis of methimazole-treated granulocytes from patients carrying NOX3 variants. In conclusion, genetic variants in NOX3 may confer susceptibility to antithyroid drug-induced apoptosis of granulocytes. These findings contribute to the understanding of the mechanisms underlying ATDAC

U2 - https://doi.org/10.1002/cpt.733

DO - https://doi.org/10.1002/cpt.733

M3 - Article

C2 - 28486791

SN - 0009-9236

VL - 102

SP - 1017

EP - 1024

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 6

ER -